ANGO - AngioDynamics, Inc.
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 50.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ANGO gains momentum as NanoKnife adoption, strong Med Tech growth and positive clinical trends support its long-term outlook.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced two-year results from the PRESERVE pivotal trial (NCT04972097) demonstrating durable oncologic control and a sustained safety profile for the NanoKnife System in the focal ablation of intermediate-risk prostate cancer. The data will be discus.
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 64.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AngioDynamics, Inc. (NASDAQ: ANGO - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has assigned a
The average of price targets set by Wall Street analysts indicates a potential upside of 65.8% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The heavy selling pressure might have exhausted for AngioDynamics (ANGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AngioDynamics tops estimates as revenue rises and losses narrow, driven by Med Tech demand, even as gross margin slips.
AngioDynamics is undervalued but remains a volatile, mixed-execution med tech story requiring patient investors. The Med Tech business continues to show robust growth—AlphaVac up 47%, NanoKnife up 21%—but margins and legacy Medical Devices drag on valuation. Q4 guidance disappointed due to increased R&D, inventory build, and ongoing tariff costs, though revenue guidance was raised.
AngioDynamics (NASDAQ: ANGO) reported fiscal 2026 third-quarter results that management described as "strong across the board," highlighted by faster growth in its MedTech segment and improved adjusted EBITDA. The company also raised its full-year outlook for net sales and adjusted EBITDA for the third consecutive quarter, citing continued execution across its core platforms. Quarterly results show
AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript
AngioDynamics (ANGO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to earnings of $0.03 per share a year ago.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2026, which ended February 28, 2026. Fiscal Year 2026 Third Quarter Highlights Quarter Ended February 28, 2026 Pro Forma* YoY Growth Net Sales $78.
Assenagon Asset Management S.A. cut its holdings in AngioDynamics, Inc. (NASDAQ: ANGO) by 19.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 237,080 shares of the medical instruments supplier's stock after selling 56,145 shares during
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2026 before the market open on Thursday, April 2, 2026. The Company's management will host a conference call at 8:00 am ET the same day to d.
Acuitas Investments LLC increased its stake in AngioDynamics, Inc. (NASDAQ: ANGO) by 12.7% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 498,530 shares of the medical instruments supplier's stock after acquiring an additional 56,300 shares during the quarter. AngioDynamics makes up
AngioDynamics, Inc. (NASDAQ: ANGO - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling 2,176,310 shares, an increase of 28.1% from the February 12th total of 1,699,336 shares. Based on an average daily volume of 276,482 shares, the
ANGO stock is buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer and broad Med Tech growth supporting margins.
Positron (OTCMKTS:POSC - Get Free Report) and AngioDynamics (NASDAQ: ANGO - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk. Earnings and Valuation This table compares Positron and AngioDynamics"s